替米沙坦联合胺碘酮治疗高血压伴阵发性心房颤动的疗效分析

目的:探讨替米沙坦联合胺碘酮治疗高血压伴阵发性心房颤动的临床疗效。方法:选取高血压伴阵发性心房颤动患者160例,随机分为试验组(替米沙坦+胺碘酮),对照组(氨氯地平+胺碘酮),各80例,观察两组治疗前后血压、左心房内径的变化及12个月内心房颤动的复发情况。结果:两组临床资料差异无统计学意义。两组均能显著降低血压(P0.01),试验组降低左心房内径疗效优于对照组(P0.05),心房颤动复发率也低于对照组(P0.05)。结论:替米沙坦能延缓高血压伴阵发性心房颤动患者的左心房内径扩大,并明显降低发颤复发率。     

替米沙坦联合胺碘酮治疗冠心病并发阵发性房颤

目的 观察替米沙坦联合胺碘酮治疗冠心病并发阵发性心房颤动(房颤)患者的窦性心律(窦律)维持作用及复发因素.方法 80例冠心病并发阵发性房颤患者随机分为两组,治疗组(替米沙坦十胺碘酮组)40例,对照组(胺碘酮组)40例.治疗12个月,观察两组患者治疗后的窦律维持率和治疗前后的左心房内径(LAD).结果 治疗12个月后,治疗组窦律维持率高于对照组(72.5%、50.0%,P＜0.05),治疗组左心房内径小于对照组,分别为(37.2士4.2)mm和(39.3±3.9)mm(P＜0.05).结论 替米沙坦联合胺碘酮治疗冠心病并发阵发性房颤,能延缓患者左心房的扩大,预防房颤复发.     

替米沙坦对老年高血压伴阵发性心房颤动患者左心房内径、超敏C反应蛋白的影响

心房颤动(AF)是老年人最常见的心律失常之一[1],国内外研究表明60～ 80岁AF患病率为1.3％～15％,且高血压是老年人AF的主要病因之一[2-4].Hylek等[5]研究显示老年人AF并发脑卒中的病死率达到24％,且存活的患者多遗留有身体残疾.已有研究显示AF的发生与心房重构有关,然而心房重构的发生与炎症反应以及肾素血管紧张素醛固酮系统(RAAS)有着非常密切联系[6].本研究旨在通过观察替米沙坦对老年高血压伴阵发性AF患者左心房内径(LAD)、血清超敏C反应蛋白(hs-CRP)及AF复发影响,以探讨其预防老年高血压患者AF的可能机制.     

小剂量胺碘酮预防阵发性房颤复发30例分析

目的：观察小剂量胺碘酮预防阵发性房颤复发的疗效。方法：选择不同病因引起的阵发性房颤患30例,给予小剂量胺碘酮治疗,预防房颤复发,观察其效果。结果：30例患随访时间为3－28（平均13．5）个月,8例患在半年内房颤复发,半年有效率为73．33％。结论：小剂量碘酮预防阵发性房颤的复发安全、有效。     

胺碘酮联合安博维预防阵发性房颤复发

目的评价胺碘酮联合安博维预防房颤的疗效。方法随机选取阵发性房颤复律后患者80例,分为治疗组（A组）和对照组（B组）各40例。B组常规口服胺碘酮及原发病治疗,A组口服胺碘酮加用安博雏150mg 1次／d及原发病的治疗。疗程12个月。结果A组治疗后房颤复发率明显下降（P〈0．01）有显著性差异。结论胺碘酮联合安博雏能有效预防阵发性房颤复发,可推广使用。     

厄贝沙坦联用胺碘酮预防心房颤动复发的临床观察

<正>心房颤动是临床常见的心律失常,大量研究显示,房颤存在明显的心房肌重构。房颤一旦发生,心房的电重构和解剖重构即启动,经药物或电复律成功后极易复发。本文旨在探讨厄贝沙坦联合胺碘酮对房颤患者逆转心房重构,减少复发的临床效果。     

辛伐他汀联合替米沙坦对并阵发性心房颤动疗效观察

目的观察辛伐他汀联合替米沙坦对阵发性心房颤动（房颤）患者的治疗疗效。方法选择阵发性房颤复律后患者58例,随机分成三组,联合替米沙坦组22例给予替米沙坦＋辛伐他汀治疗,辛伐他汀组18例口服辛伐他汀治疗,对照组18例仅给予常规治疗,随访1年,观察心房颤动转复窦性心律后1年房颤复发率,结果治疗后,联合替米沙坦组患者心房颤动的复发率明显少于对照组（P〈0.05）。结论辛伐他汀联合替米沙坦治疗可以减少阵发性房颤的复发。     

厄贝沙坦联合胺碘酮治疗阵发性心房纤颤86例临床观察

目的探讨厄贝沙坦联合胺碘酮治疗阵发性心房颤动的临床疗效。方法将86例阵发性心房颤动的患者分为治疗组和对照组,均给予胺碘酮治疗,治疗组加用厄贝沙坦,疗程均为1年。比较两组治疗后第3、6、12个月的窦性心律维持率和治疗后第6、12个月的左心房内径。结果治疗后第3、6个月治疗组窦性心律的维持率分别为87％和80％,高于对照组的84％和71％,两组间比较差异无统计学意义（P〉0．05）,而治疗后12个月后,治疗组的窦性心律维持率为77％,对照组为58％,两组间比较差异有统计学意义（P〈0．05）。治疗组治疗前、治疗后第6个月和第12个月的左心房内径分别为（39．8±1．4）mm、（38．3±1．9）mm、（37．5±1．6）mm;对照组为（38．7±1．7）mm、（38．7±1．7）mm、（39．8±1．5）mm,两组治疗12个月后左心房内径比较差异有统计学意义（P〈0．05）。结论厄贝沙坦联合胺碘酮治疗阵发性心房颤动,预防心房颤动复发的疗效显著优于单用胺碘酮,并有延缓左心房扩大的作用。     

小剂量胺碘酮预防阵发性房颤远期疗效观察

目的：观察小剂量胺碘酮预防阵发性房颤的远期疗效。方法：40例阵发性房颤病人经静注西地兰恢复窦性心律后口服胺碘酮，观察其维持窦性心律情况，及对甲状腺、肝、肾功能的影响。结果：平均随访18个月，1年有效率达75％，房颤复发心室率较前显降低（P＜0.05)。结论：长期应用小剂量胺碘酮预防阵发性房颤比较安全，有效，副作用小，值得临床广泛应用。     

P波离散度对脑卒中患者并发阵发性房颤及预后的预测价值

目的 探讨P波离散度对脑卒中患者发生阵发性房颤及预后的预测价值.方法 选择72例脑卒中患者,根据有无阵发性房颤分为A组（伴有阵发性房颤）36例和B组（不伴有阵发性房颤）36例,两组患者均行12导联心电图及彩色多普勒超声心动图,24h动态心电图检测,分别测量心电图P波最大时限（Pmax）、P波最小时限（Pmin）,计算P波离散度（Pd）、左心房内径（LAD）、左心室射血分数（LVEF）,并进行比较.结果 两组间P波最大时限（Pmax）、P波离散度（Pd）、左心房内径（LAD）、左心室射血分数（LVEF）、频发房早、短阵房速比较,差异有统计学意义（P＜0.05）.结论 P波离散度是预测脑卒中患者并发阵发性房颤的可靠指标,对预后观测有一定意义.     

瑞舒伐他汀和替米沙坦对原发性高血压并发阵发性心房纤颤治疗的影响

目的:观察瑞舒伐他汀和替米沙坦对原发性高血压(EH)并发阵发性心房纤颤(AF)患者心电图P波时限和离散度及AF发生率的影响。方法:EH并发阵发性AF患者56例,随机分为2组:替米沙坦(80 mg/d)加瑞舒伐他汀(10 mg/d)组(联合用药组)和替米沙坦(80 mg/d)组。共观察6个月。分别于用药前后测定12导联体表心电图中P波的时限和P波离散度及AF发生率。结果:用药后两组均可使EH并发阵发性EH患者心电图P波的时限和P波离散度减小,组间比较显示,联合用药组的作用优于单用替米沙坦组。结论:瑞舒伐他汀合用替米沙坦对EH并发阵发性AF患者窦律的维持及预防AF发生的作用优于单用替米沙坦。     

Predictive value of HMGB1 for atrial fibrillation recurrence after cryoballoon ablation in paroxysmal atrial fibrillation patients

BackgroundCryoballoon ablation (CBA) is recommended for patients with symptomatic drug refractory paroxysmal atrial fibrillation (pAF). However, substantial atrial fibrillation (AF) recurrence is common during follow‐up. Searching for a potential biomarker representing both myocardial injury and inflammation to identify patients at high risk of AF recurrence after CBA is very meaningful for postoperative management of AF patients.HypothesisTo evaluate the clinical efficacy of high‐mobility group box 1 (HMGB1) protein released from the left atrium to predict AF recurrence in pAF patients after CBA at 1‐year follow‐up.MethodsWe included 72 pAF patients who underwent CBA. To determine the expression levels of HMGB1, left atrial blood samples were collected from the patients before CBA and after the procedure through the transseptal sheath. Patients were followed up for AF recurrence for 1 year.ResultsA total of 19 patients of the 72 experienced AF recurrence. The level of postoperative HMGB1 (HMGB1post) was higher in the AF recurrence group than in the AF non recurrence group (p = .03). However, no differences were noted in the levels of other biomarkers such as preoperative high‐sensitivity C‐reactive protein (hs‐CRP), postoperativehs‐CRP, and preoperative HMGB1 between the two groups. Multiple logistic regression analysis revealed that a higher level of serum HMGB1post was associated with AF recurrence (odds ratio: 5.29 [1.17–23.92], p = .04). Receiver operating characteristic analysis revealed that HMGB1post had a moderate predictive power for AF recurrence (area under the curve: 0.68; sensitivity: 72%; and specificity: 68%). The 1‐year AF‐free survival was significantly lower in patients with a high HMGB1post level than in those with a low HMGB1post level (hazard ratio: 3.81 [1.49–9.75], p = .005).ConclusionIn pAF patients who under went CBA, the level of HMGB1 after CBA was associated with AF recurrence and demonstrated a moderate predictive power. Thus, we offer a potential biomarker to identify pAF patients at high risk of AF recurrence.     

瑞舒伐他汀联合贝那普利对阵发性心房颤动患者的治疗效果及其作用机制

目的观察瑞舒伐他汀与贝那普利联合应用对阵发性房颤的治疗效果及其作用机制。方法：入选70例阵发性房颤患者,随机分为试药组（口服胺碘酮＋瑞舒伐他汀＋贝那普利）及对照组（口服胺碘酮）,比较两组患者房颤治疗效果、c反应蛋白（CRP）水平及左房内径（LAD）。结果：经过6个月的随访,与对照组比较,试药组房颤发作次数、房颤持续时间显著下降,总有效率提高,差异均具有显著性（P〈0．05）。且CPR水平、LAD显著低于对照组（均P〈0．05）。结论：瑞舒伐他汀联合贝那普利可以减少房颤发生,其机制可能与减少炎症反应,抑制心肌重构有关。     

Clinical outcome of very late recurrence of atrial fibrillation after catheter ablation of paroxysmal atrial fibrillation

INTRODUCTION: High recurrence rate is still a major problem associated with ablation of paroxysmal atrial fibrillation (AF). Most of the recurrences occur within 6 months after ablation. The characteristics of very late recurrent AF (>12 months after ablation) have not been reported. METHODS AND RESULTS: Two hundred seven patients with drug-refractory AF underwent successful focal ablation or isolation of AF foci. After the first ablation procedure, Holter monitoring and event recorders were used to evaluate symptomatic recurrent AF. A second ablation procedure was recommended if the antiarrhythmic drugs could not control recurrent AF. During long-term follow-up (mean 30 +/- 11 months, up to 51 months), 70 patients had recurrent AF, including 13 patients (6%) with very late (>12 months) recurrent AF (group 1) and 57 patients (28%) with late (within 12 months after ablation) recurrent AF (group 2). Group 1 patients had a significantly lower incidence of multiple (> or = 2) AF foci (23% vs 63%, P = 0.02) than group 2 patients. In addition, the incidence of antiarrhythmic drugs use (38% vs 84%, P = 0.001) to maintain sinus rhythm after the first episode of recurrent AF was significantly lower in group 1 than group 2 patients, and the incidence of a second intervention procedure (8% vs 35%, P = 0.051) tended to be lower in group 1 than group 2 patients. CONCLUSION: The incidence of very late recurrent AF after ablation of paroxysmal AF is very low, and the clinical outcome of patients with very late recurrent AF is benign.     

阵发性房颤、房扑的心电散点图特征

目的观察阵发性房扑、房颤的心电散点图特征,并探讨其临床意义。方法选择20例阵发性房扑、房颤患者的24小时动态心电图,回顾分析其心电散点图。结果 20例阵发性房颤、房扑患者中,17例可以通过心电散点图区分出不同心律,占总例数85%;3例无法通过心电散点图区分出不同的心律,占总例数15%。结论阵发性房扑一般可以通过心电散点图迅速鉴别,阵发性房颤绝大多数病例可以通过心电散点图迅速鉴别,心电散点图有助于提高海量心电信息中阵发性房扑房颤的分析效率。此外,心电散点图可以获得更多的生理状态下整体动态的心电信息。     

Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation

Aims. To test the hypothesis that stroke and systemic embolic events (SEE) in the stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) III and V trials are different between paroxysmal and persistent atrial fibrillation (AF). Methods. Data analysis from two cohorts of patients enroled in the prospective SPORTIF III and V clinical trials (n = 7329); 836 subjects (11.4%) with paroxysmal AF [mean age 70.1 years (SD = 9.5)] were compared with 6493 subjects with persistent AF for this ancillary study. Results. The annual event rates for stroke/SEE are 1.73% for persistent AF and 0.93% for paroxysmal AF. In a multivariate analysis, after adjusting for stroke risk factors, gender and aspirin usage, the differences remained statistically significant with a higher hazard ratio (HR) for stroke/SEE in persistent AF [vs. paroxysmal AF, HR 1.87, 95% confidence interval (CI) 1.04–3.36; P = 0.037]. In ‘high risk’ patients (with ≥2 stroke risk factors) annual event rates for stroke/SEE were 2.08% for persistent AF and 1.27% for paroxysmal AF (adjusted HR = 1.68, 95% CI 0.91–3.1, P = 0.098). Elderly patients had annual event rates for stroke/SEE of 2.38% for persistent AF and 1.13% for paroxysmal AF (adjusted HR = 2.27, 95% CI 0.92–5.59, P = 0.075). Vitamin K antagonist (VKA)‐naïve paroxysmal AF patients had a 1.89%/year stroke/SEE rate, compared with 0.61% for previous VKA takers (HR = 0.33, 95% CI 0.11–1.01, P = 0.052). Conclusion. In this large clinical trial cohort of anticoagulated AF patients, those with paroxysmal AF had stroke rates which were lower than for patients with persistent AF, although both groups had broadly similar stroke risk factors. Subjects with paroxysmal AF at ‘high risk’ had stroke/SEE rates that were not significantly different to persistent AF subjects.     

The effects of aging on atrial endocardial electrograms in patients with paroxysmal atrial fibrillation

BACKGROUND: The prevalence of atrial fibrillation (AF) has been reported to increase with advancing age. Histologic studies in AF have demonstrated that the percentage of fibrosis and degenerative changes in the atrial muscle increase significantly with age. HYPOTHESIS: This study was undertaken to assess the influence of advancing age on atrial endocardial electrograms recorded during sinus rhythm in patients with paroxysmal atrial fibrillation (PAF), which had not been assessed previously. METHODS: Right atrial endocardial catheter mapping during sinus rhythm was performed in 111 patients with PAF to evaluate the influence of advancing age on atrial endocardial electrograms. The bipolar electrograms were recorded at 12 sites in the right atrium, and an abnormal atrial electrogram was defined as lasting > or = 100 ms, and/or showing eight or more fragmented deflections. RESULTS: In all, 1,332 right atrial endocardial electrograms were assessed and measured quantitatively. The number of abnormal atrial electrograms in patients with PAF showed a significantly positive correlation with age (r = 0.34; p < 0.0005). Patients aged > 60 years had a significantly greater mean number of abnormal electrograms (2.58 +/- 2.05) than those aged < 60 years (1.43 +/- 2.03; p < 0.004). The longest duration (r = 0.35; p < 0.0005) and the maximal number of fragmented deflections (r = 0.29; p < 0.005) of atrial electrograms among the 12 right atrial sites also showed a significantly positive correlation with age. CONCLUSIONS: Aging alters the electrophysiologic properties of the atrial muscle in patients with PAF. Elderly patients have a significantly greater abnormality of atrial endocardial electrograms than do younger ones. There is a progressive increment in the extension of altered atrial muscle with advancing age in patients with PAF.     

阵发性孤立性房颤患者血浆B型钠利尿肽水平的研究

目的研究无器质性心脏疾患的房颤（AF）患者血浆B型钠利尿肽（BNP）水平。方法连续测定61例AF患者和61例年龄、性别相匹配的健康受试者的血浆BNP水平。结果AF组血浆BNP水平明显高于对照组（P〈0.01）。多元回归分析结果显示,年龄、左房内径和AF病程是血浆BNP升高的独立预测因素（P〈0.01）。结论阵发性孤立性AF患者BNP水平升高,其升高与AF直接相关但并非由左室功能障碍所致。